Clinical information of HIFU

Indications for Ablatherm® HIFU

Clinically Localized Prostate Cancer:

  • •First choice therapy (T-1, T-2)
  • •Curative Salvage therapy for local recurrence after EBRT

Ablatherm® HIFU is approved in Canada and has undergone the most extensive research, development and testing. Ablatherm® HIFU is presently being used in England, Belgium, France, Italy, Germany, Russia, South Korea, and other Asian countries.

Histology

histology - 48 hours

48 hours: .

Complete destruction of the glandular tissue due to coagulation necrosis which reaches the capsule and the periprostatic fat.

 


3 months:

The necrotic prostatic tissue is replaced by a fibrotic tissue (including the capsule)

MRI Post-Treatment

MRI of the prostate after an Ablatherm® HIFU session (the whole prostate volume is treated)

 
Transversal plane   Longitudinal plane

MRI examinations performed early after the HIFU treatment of prostate cancer cannot give a qualitative assessment of the necrosis. It does however, allow a precise evaluation of the treated volume as demonstrated in a clinical trial. After gadolinium injection, the treated area appeared as a hypo-intense area and a surrounding 6-8 mm ring of contrast enhancement. Biopsies were taken in the ring, and these also demonstrated complete necrosis in this ring.

Learn more about the HIFU clinical study results

 

PSA Post-Treatment

Typical PSA evolution after a single treatment session

(complete treatment of the gland)

hifu session PSA post-treatment

  • Elevated PSA level before the treatment of prostate cancer
  • Peak in PSA immediately after the session
  • Nadir PSA obtained 3 months after the treatment
  • Low and stable follow-up PSA level at 0.2 ng/ml

PSA evolution after the first nerve sparing treatment
(need for a second session)

PSA session 2

  • Elevated PSA level before the treatment of prostate cancer
  • Peak in PSA immediately after the first session
  • Nadir PSA obtained within 3 months after the 1st session and showing a residual PSA level
  • Rising PSA level following the Nadir with residual positive biopsies; indication for a 2nd treatment session
  • Then, low and stable follow-up PSA level